Hera BioLabs
Valeriya Adjan Steffey, M.D., is a seasoned medical professional with extensive experience in biopharmaceuticals and clinical consulting. Currently serving as the Director of In-Vitro Studies at Hera BioLabs since December 2018, Valeriya leads organizational change and ensures compliance with safety and regulatory policies. In addition, Valeriya provides independent consulting services for Demeetra AgBio, Inc., focusing on cell culture and in vitro assays. Previous roles include Director of Cell Line Engineering and Manager of Cell Culture at Transposagen Biopharmaceuticals, where Valeriya cultivated customer relationships and led innovative projects in cell biology. Valeriya's career also encompasses significant contributions as a Scientist II at the University of Kentucky and as an ophthalmologist in Russian medical facilities. Valeriya holds two medical degrees from Rostov State Medical University, specializing in ophthalmology and general medicine.
This person is not in any teams
Hera BioLabs
Hera BioLabs is an innovative pre-clinical contract services, products & licensing company. Our mission is to use cutting-edge gene-editing technologies to accelerate pre-clinical research and drug development. Whether your focus is on xenograft/PDX drug efficacy studies, gene editing, or research model creation, our team can help boostyour preclinical research.Using our gene editing tools, Hera built the SRG™ platform, a double knockout Sprague-Dawley rat engineered for T-cell, B-cell, and NK cell deficiency. Our first SRG model is the SRG OncoRat®, larger and a valuable complement and in some cases alternative to oncology studies in mice, OncoRat is uniquely suited for xenograft oncology studies given its excellent tumor take-rates and smooth transition from efficacy to safety. Animal studies are conducted by our experienced staff in our on-site vivarium that features a dual HEPA-filtered, disposable IVC rodent caging system.